Ann: December 2023 Quarterly Activities Report, page-34

The commentary from Miller was just awful. What he needed to tell the market is where they are at with commercialisation and when the Gen4 would get FDA approval.
I am not too concerned about the headline number as they are invoicing on 60 day terms so apart from direct on line sales all other sales would be those invoiced before 31st Oct to allow for payment by 31st Dec. There was a delay in rollout.
What Miller needed to do was tell the market how shipping went during the last quarter.
He needs to go, he is simply not fit for the role.
Perhaps those are the questions for the webinar? When is he going.